159 related articles for article (PubMed ID: 31005213)
1. Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours.
Lenglet A; Campeau MP; Mathieu D; Bahig H; Lambert L; Vu T; Roberge D; Bilodeau L; Filion E
Radiother Oncol; 2019 May; 134():178-184. PubMed ID: 31005213
[TBL] [Abstract][Full Text] [Related]
2. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
Meng MB; Wang HH; Zaorsky NG; Sun BS; Zhu L; Song YC; Li FT; Dong Y; Wang JS; Chen HM; Yu XY; Yuan ZY
Cancer Sci; 2019 Nov; 110(11):3553-3564. PubMed ID: 31464032
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
4. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer.
Yang D; Cui J; Zhao J; You J; Yu R; Yu H; Jiang L; Li D; Xu B; Shi A
Thorac Cancer; 2020 Mar; 11(3):754-761. PubMed ID: 32012484
[TBL] [Abstract][Full Text] [Related]
7. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review.
Chen H; Laba JM; Zayed S; Boldt RG; Palma DA; Louie AV
J Thorac Oncol; 2019 Aug; 14(8):1332-1342. PubMed ID: 31075543
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy.
Duijm M; van der Voort van Zyp NC; Granton PV; van de Vaart P; Mast ME; Oomen-de Hoop E; Hoogeman MS; Nuyttens JJ
Acta Oncol; 2020 Jul; 59(7):809-817. PubMed ID: 32286140
[No Abstract] [Full Text] [Related]
10. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer.
Cong Y; Sun B; Wang J; Meng X; Xuan L; Zhang J; Liu J; Shen G; Wu S
Thorac Cancer; 2019 Jul; 10(7):1567-1575. PubMed ID: 31187604
[TBL] [Abstract][Full Text] [Related]
12. Treatment completion, treatment compliance and outcomes of old and very old patients treated by dose adapted stereotactic ablative radiotherapy (SABR) for T1-T3N0M0 non-small cell lung cancer.
Mihai A; Milano MT; Santos A; Kennedy A; Thirion P; McDermott RS; Westrup J; Rock L; Armstrong J
J Geriatr Oncol; 2019 May; 10(3):442-448. PubMed ID: 30420322
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: a single institution real life experience.
Guillaume E; Tanguy R; Ayadi M; Claude L; Sotton S; Moncharmont C; Magné N; Martel-Lafay I
Br J Radiol; 2022 Jan; 95(1129):20210533. PubMed ID: 34797724
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer.
Brooks ED; Sun B; Zhao L; Komaki R; Liao Z; Jeter M; Welsh JW; O'Reilly MS; Gomez DR; Hahn SM; Heymach JV; Rice DC; Chang JY
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):900-907. PubMed ID: 28258887
[TBL] [Abstract][Full Text] [Related]
15. A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor.
Park S; Kim Y; Yoon WS; Rim CH
Int J Radiat Biol; 2019 Sep; 95(9):1287-1294. PubMed ID: 31145016
[No Abstract] [Full Text] [Related]
16. Radiomics for prediction of radiation-induced lung injury and oncologic outcome after robotic stereotactic body radiotherapy of lung cancer: results from two independent institutions.
Bousabarah K; Blanck O; Temming S; Wilhelm ML; Hoevels M; Baus WW; Ruess D; Visser-Vandewalle V; Ruge MI; Treuer H; Kocher M
Radiat Oncol; 2021 Apr; 16(1):74. PubMed ID: 33863358
[TBL] [Abstract][Full Text] [Related]
17. Outcome of conventional radiotherapy in small centrally located tumours or lymph nodes: minimal toxicity, remarkable survival but challenging loco-regional control.
Knap MM; Khan S; Khalil AA; Møller DS; Hoffmann L
Acta Oncol; 2023 Nov; 62(11):1433-1439. PubMed ID: 37707506
[TBL] [Abstract][Full Text] [Related]
18. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
[TBL] [Abstract][Full Text] [Related]
19. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
20. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors.
Nguyen KNB; Hause DJ; Novak J; Monjazeb AM; Daly ME
Pract Radiat Oncol; 2019 Mar; 9(2):e196-e202. PubMed ID: 30496842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
